Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Page Path

HOME
ARTICLE CATEGORY
Review

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 7801 Download: 510 Web of Science: 46 Crossref: 46

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 5573 Download: 260 Web of Science: 27 Crossref: 29

Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology

Sung Hak Lee, Hyun-Jong Jang

Clin Mol Hepatol. 2022;28(4):754-772. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2021.0394

View: 6066 Download: 242 Web of Science: 9 Crossref: 9

Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review

Sang Jin Kim, Jong Man Kim

Clin Mol Hepatol. 2022;28(4):739-753. Published online April 26, 2022

DOI: https://doi.org/10.3350/cmh.2022.0060

View: 5263 Download: 176 Web of Science: 13 Crossref: 15

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 5427 Download: 257 Web of Science: 13 Crossref: 14

The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology

Youngseok Lee, Jong-Hoon Kim

Clin Mol Hepatol. 2022;28(4):706-724. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0390

View: 13287 Download: 280 Web of Science: 11 Crossref: 12

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 8269 Download: 391 Web of Science: 13 Crossref: 14

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 9228 Download: 647 Web of Science: 39 Crossref: 44

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Mina Komuta

Clin Mol Hepatol. 2022;28(3):396-407. Published online January 14, 2022

DOI: https://doi.org/10.3350/cmh.2021.0287

View: 6512 Download: 360 Web of Science: 16 Crossref: 17

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Myung Ji Goh, Dong Hyun Sinn

Clin Mol Hepatol. 2022;28(3):380-395. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0366

View: 5337 Download: 183 Web of Science: 12 Crossref: 12

Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon

Clin Mol Hepatol. 2022;28(3):362-379. Published online December 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0361

View: 6532 Download: 239 Web of Science: 18 Crossref: 20

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

View: 5659 Download: 260 Web of Science: 19 Crossref: 19

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0308

View: 17478 Download: 374 Web of Science: 25 Crossref: 28

Cost-effectiveness of chronic hepatitis C screening and treatment

Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim

Clin Mol Hepatol. 2022;28(2):164-173. Published online December 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0193

View: 5873 Download: 214 Web of Science: 14 Crossref: 12

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0310

View: 8219 Download: 383 Web of Science: 61 Crossref: 61

Approaches to quantifying hepatitis B virus covalently closed circular DNA

Henrik Zhang, Thomas Tu

Clin Mol Hepatol. 2022;28(2):135-149. Published online October 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0283

View: 7700 Download: 379 Web of Science: 13 Crossref: 14

The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls

Hae Lim Lee, Sung Won Lee

Clin Mol Hepatol. 2022;28(2):121-134. Published online September 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0239

View: 7009 Download: 386 Web of Science: 20 Crossref: 19

Current knowledge about biomarkers of acute kidney injury in liver cirrhosis

Han Ah Lee, Yeon Seok Seo

Clin Mol Hepatol. 2022;28(1):31-46. Published online August 2, 2021

DOI: https://doi.org/10.3350/cmh.2021.0148

View: 7121 Download: 327 Web of Science: 11 Crossref: 14

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 10517 Download: 652 Web of Science: 33 Crossref: 34

The management of post-transplantation recurrence of hepatocellular carcinoma

Luckshi Rajendran, Tommy Ivanics, Marco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin

Clin Mol Hepatol. 2022;28(1):1-16. Published online October 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0217

View: 8941 Download: 350 Web of Science: 33 Crossref: 36

Recent advances in nonalcoholic fatty liver disease metabolomics

Hwi Young Kim

Clin Mol Hepatol. 2021;27(4):553-559. Published online June 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0127

View: 10695 Download: 499 Web of Science: 42 Crossref: 45

Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis

Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim

Clin Mol Hepatol. 2021;27(4):535-552. Published online June 16, 2021

DOI: https://doi.org/10.3350/cmh.2021.0109

View: 11372 Download: 622 Web of Science: 6 Crossref: 6

Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0012

View: 13735 Download: 363 Web of Science: 22 Crossref: 25

Changes in the epidemiology and management of bacterial infections in cirrhosis

Salvatore Piano, Marta Tonon, Paolo Angeli

Clin Mol Hepatol. 2021;27(3):437-445. Published online January 28, 2021

DOI: https://doi.org/10.3350/cmh.2020.0329

View: 8253 Download: 424 Web of Science: 35 Crossref: 40

β-blockers in advanced cirrhosis: More friend than enemy

Ki Tae Yoon, Hongqun Liu, Samuel S. Lee

Clin Mol Hepatol. 2021;27(3):425-436. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0234

View: 7313 Download: 287 Web of Science: 28 Crossref: 28

Anti-fibrotic treatments for chronic liver diseases: The present and the future

Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada

Clin Mol Hepatol. 2021;27(3):413-424. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0187

View: 14643 Download: 484 Web of Science: 28 Crossref: 29

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0179

View: 6546 Download: 261 Web of Science: 33 Crossref: 31

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 9317 Download: 437 Web of Science: 65 Crossref: 65

Current and future strategies for the treatment of chronic hepatitis C

Omar Alshuwaykh, Paul Y. Kwo

Clin Mol Hepatol. 2021;27(2):246-256. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0230

View: 6377 Download: 241 Web of Science: 14 Crossref: 15

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0204

View: 9042 Download: 391 Web of Science: 42 Crossref: 41

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 5164	MAFLD: How is it different from NAFLD?
Viewed By 4910	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4606	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4579	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach